Biogen Inc. Faces Setback as INESSS Recommends Against Reimbursement for SKYCLARYS™ in Quebec Despite Approval for Friedreich Ataxia Treatment

Reuters

2025/06/05

Biogen Inc. Faces Setback as INESSS Recommends Against Reimbursement for SKYCLARYS™ in Quebec Despite Approval for Friedreich Ataxia Treatment

Biogen Inc. has announced the approval of SKYCLARYS™ (omaveloxolone) by Health Canada as the first and only treatment in Canada specifically targeting the underlying mechanisms of Friedreich ataxia $(FA)$ in patients aged 16 and older. This approval was granted under Health Canada's Priority Review process. Despite this significant milestone, Biogen has expressed disappointment over the recommendation by INESSS against listing SKYCLARYS for reimbursement in Quebec, which would leave FA patients in the province without public access to this critical treatment. The approval of SKYCLARYS marks a breakthrough for FA patients, addressing a major gap in care and offering hope for improved quality of life. The decision now awaits further consideration for reimbursement by Quebec authorities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via CNW (Ref. ID: C4697) on June 05, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2541228660"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541228660\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2541228660?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-05 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541228660","market":"nz","top_or_hot":-1,"title":"Biogen Inc. Faces Setback as INESSS Recommends Against Reimbursement for SKYCLARYS™ in Quebec Despite Approval for Friedreich Ataxia Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Biogen Inc. Faces Setback as INESSS Recommends Against Reimbursement for SKYCLARYS™ in Quebec Despite Approval for Friedreich Ataxia Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Biogen Inc. has announced the approval of SKYCLARYS™ (omaveloxolone) by Health Canada as the first and only treatment in Canada specifically targeting the underlying mechanisms of Friedreich ataxia <a href=\"https://laohu8.com/S/FA\">$(FA)$</a> in patients aged 16 and older. This approval was granted under Health Canada's Priority Review process. Despite this significant milestone, Biogen has expressed disappointment over the recommendation by INESSS against listing SKYCLARYS for reimbursement in Quebec, which would leave FA patients in the province without public access to this critical treatment. The approval of SKYCLARYS marks a breakthrough for FA patients, addressing a major gap in care and offering hope for improved quality of life. The decision now awaits further consideration for reimbursement by Quebec authorities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via CNW (Ref. ID: C4697) on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen Inc. Faces Setback as INESSS Recommends Against Reimbursement for SKYCLARYS™ in Quebec Despite Approval for Friedreich Ataxia Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen Inc. Faces Setback as INESSS Recommends Against Reimbursement for SKYCLARYS™ in Quebec Despite Approval for Friedreich Ataxia Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-05 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Biogen Inc. Faces Setback as INESSS Recommends Against Reimbursement for SKYCLARYS™ in Quebec Despite Approval for Friedreich Ataxia Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Biogen Inc. has announced the approval of SKYCLARYS™ (omaveloxolone) by Health Canada as the first and only treatment in Canada specifically targeting the underlying mechanisms of Friedreich ataxia <a href=\"https://laohu8.com/S/FA\">$(FA)$</a> in patients aged 16 and older. This approval was granted under Health Canada's Priority Review process. Despite this significant milestone, Biogen has expressed disappointment over the recommendation by INESSS against listing SKYCLARYS for reimbursement in Quebec, which would leave FA patients in the province without public access to this critical treatment. The approval of SKYCLARYS marks a breakthrough for FA patients, addressing a major gap in care and offering hope for improved quality of life. The decision now awaits further consideration for reimbursement by Quebec authorities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via CNW (Ref. ID: C4697) on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL6GC1HR:1","article_id":"2541228660","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541228660","pubTimestamp":1749121265,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biogen Inc. Faces Setback as INESSS Recommends Against Reimbursement for SKYCLARYS in Quebec Despite Approval for Friedreich Ataxia Treatment. Biogen Inc. has announced the approval of SKYCLARYS  by Health Canada as the first and only treatment in Canada specifically targeting the underlying mechanisms of Friedreich ataxia  in patients aged 16 and older. This approval was granted under Health Canada's Priority Review process. Despite this significant milestone, Biogen has expressed disappointment over the recommendation by INESSS against listing SKYCLARYS for reimbursement in Quebec, which would leave FA patients in the province without public access to this critical treatment. The approval of SKYCLARYS marks a breakthrough for FA patients, addressing a major gap in care and offering hope for improved quality of life. The decision now awaits further consideration for reimbursement by Quebec authorities.Disclaimer: This news brief was created by Public Technologies  using generative art","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BK4588":"碎股","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BK4585":"ETF&股票定投概念","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4139":"生物科技","BK4532":"文艺复兴科技持仓","BIIB":"渤健公司","BK4533":"AQR资本管理(全球第二大对冲基金)"},"translate_title":"尽管批准了Friedreich共济失调治疗，但由于INESSS建议不要报销魁北克省SKYCLARYS™的费用，Biogen Inc.仍面临挫折","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":0.9},"content_text":"Biogen Inc. Faces Setback as INESSS Recommends Against Reimbursement for SKYCLARYS™ in Quebec Despite Approval for Friedreich Ataxia Treatment\n    \n\n        Biogen Inc. has announced the approval of SKYCLARYS™ (omaveloxolone) by Health Canada as the first and only treatment in Canada specifically targeting the underlying mechanisms of Friedreich ataxia $(FA)$ in patients aged 16 and older. This approval was granted under Health Canada's Priority Review process. Despite this significant milestone, Biogen has expressed disappointment over the recommendation by INESSS against listing SKYCLARYS for reimbursement in Quebec, which would leave FA patients in the province without public access to this critical treatment. The approval of SKYCLARYS marks a breakthrough for FA patients, addressing a major gap in care and offering hope for improved quality of life. The decision now awaits further consideration for reimbursement by Quebec authorities.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via CNW (Ref. ID: C4697) on June 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}